肿瘤细胞治疗研究
英文原题：Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.
套细胞淋巴瘤（MCL）是Non-Hodgkins B细胞淋巴瘤中最致命的类型之一。
套细胞淋巴瘤（MCL）是Non-Hodgkins B细胞淋巴瘤中最致命的类型之一。通常，患者表现为CyclinD1过表达以及通过基因组测序鉴定的继发性突变。尽管MCL患者最初可能对治疗有反应，但最终会复发并死于疾病，这凸显了寻找新治疗靶点的迫切需求。在此，我们对健康B细胞和三种不同形式的B细胞恶性肿瘤（包括MCL）进行了蛋白质组学分析，以定义MCL的蛋白质组学特征。我们将每种细胞的蛋白质组与MCL进行比较，鉴定出10种在MCL中特异性上调的蛋白质。在这10种蛋白质中，有7种未显示转录水平的变化，被传统的RNA表达分析所忽视。对蛋白质组学特征的进一步分析揭示了CAR T细胞治疗中双靶向的潜在途径，并为基于蛋白质表达的个性化治疗提供了指导。
Mantle cell lymphoma (MCL) is one of the deadliest forms of Non-Hodgkins B-cell lymphoma. Typically, patients present with both overexpression of CyclinD1 and secondary mutations identified by genomic sequencing. Although MCL patients may initially respond to treatment, they eventually relapse and succumb to disease, highlighting the essential need to identify new targets for treatment. Here we performed proteomic profiling of healthy B cells and three different forms of B-cell malignancies, including MCL, to define the proteomic signature of MCL. We compared the proteome of each to MCL and identified 10 proteins that are specifically upregulated in MCL. Of these 10 proteins, seven of them show no transcriptional changes and have been overlooked by conventional RNA expression analysis. Further analysis of the proteomic signature reveals potential avenues for dual targeting in CAR T-cell therapy and provides guidance for personalized therapeutics based on protein expression.
MEMBER ACCOUNT
登录成功会直接打开下一页。
